Analytical Data
-
Gene name
GRIN2D
- Application
-
Alternative Names
GRIN2D；GluN2D；NMDAR2D；Glutamate receptor ionotropic. NMDA 2D
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O15399
-
Expression Region
全长
-
AA Sequence
full
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GRIN2D, a member of the NMDA receptor family, has gained significant attention in neuroscience research due to its unique properties and potential implications in various neuropsychiatric disorders. NMDA receptors are critical for synaptic plasticity and memory function, and GRIN2D is characterized by its distinct subunit composition, influencing receptor function and signaling pathways. Studies have shown that GRIN2D is involved in both excitatory neurotransmission and neurodevelopmental processes. Abnormalities in NMDA receptor function, including those associated with GRIN2D, have been linked to conditions such as schizophrenia, autism spectrum disorders, and Alzheimer's disease. Recent advances in recombinant protein technology have enabled researchers to produce and study GRIN2D in vitro, facilitating a deeper understanding of its structural and functional properties. By investigating GRIN2D's role in receptor assembly, pharmacology, and interactions with other signaling molecules, researchers aim to uncover novel therapeutic targets to ameliorate the symptoms associated with NMDA receptor dysfunction. Overall, the study of GRIN2D recombinant proteins holds promise for advancing our knowledge of NMDA receptor biology and developing innovative treatment strategies for neuropsychiatric conditions.
